|
|
Vaccine Detail
|
AMA 49-CPE |
| Vaccine Information |
- Vaccine Name: AMA 49-CPE
- Target Pathogen: Plasmodium spp.
- Target Disease: Malaria
- Type: Virosome-formulated synthetic peptides
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Antigen: A virosome-formulated P. falciparum protein derived synthetic peptide antigen (Genton et al., 2007)
- AMA1 from P. falciparum 3D7
gene engineering:
- Type: Conjugate vaccine preparation
- Description: AMA 49-CPE is prepared as an apical membrane antigen-1 (AMA-1) derived synthetic phospatidylethanolamine (PE)-peptide conjugate (Genton et al., 2007)
- Detailed Gene Information: Click Here.
- Immunization Route: Intramuscular injection (i.m.)
- Description: AMA 49-CPE is an apical membrane antigen-1 (AMA-1) derived synthetic phospatidylethanolamine (PE)-peptide conjugate that serves as a malaria vaccine (Genton et al., 2007)
|
| Host Response |
|
Human Response
- Host Strain: healthy Caucasian volunteers aged 18-45 years
- Immune Response: 50 microg antigen dose was associated with a higher mean antibody titer and seroconversion rate than the 10 microg dose (Genton et al., 2007)
- Side Effects: 11/46 study participants reported 16 vaccine related local AEs of being in pain (Genton et al., 2007)
|
| References |
Genton et al., 2007: Genton B, Pluschke G, Degen L, Kammer AR, Westerfeld N, Okitsu SL, Schroller S, Vounatsou P, Mueller MM, Tanner M, Zurbriggen R. A randomized placebo-controlled phase Ia malaria vaccine trial of two virosome-formulated synthetic peptides in healthy adult volunteers. PloS one. 2007; 2(10); e1018. [PubMed: 17925866].
|
|
